AU2012325758A1 - Antigen presenting cancer vaccine with gamma interferon - Google Patents

Antigen presenting cancer vaccine with gamma interferon

Info

Publication number
AU2012325758A1
AU2012325758A1 AU2012325758A AU2012325758A AU2012325758A1 AU 2012325758 A1 AU2012325758 A1 AU 2012325758A1 AU 2012325758 A AU2012325758 A AU 2012325758A AU 2012325758 A AU2012325758 A AU 2012325758A AU 2012325758 A1 AU2012325758 A1 AU 2012325758A1
Authority
AU
Australia
Prior art keywords
cells
melanoma
gamma
ifn
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012325758A
Other languages
English (en)
Inventor
Andrew CORNFORTH
Robert DILLMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Publication of AU2012325758A1 publication Critical patent/AU2012325758A1/en
Assigned to NEOSTEM ONCOLOGY, LLC reassignment NEOSTEM ONCOLOGY, LLC Alteration of Name(s) of Applicant(s) under S113 Assignors: CALIFORNIA STEM CELL, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/30—Coculture with; Conditioned medium produced by tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2012325758A 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon Abandoned AU2012325758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549681P 2011-10-20 2011-10-20
US61/549,681 2011-10-20
US201261594304P 2012-02-02 2012-02-02
US61/594,304 2012-02-02
PCT/US2012/061294 WO2013059778A2 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon

Publications (1)

Publication Number Publication Date
AU2012325758A1 true AU2012325758A1 (en) 2014-04-24

Family

ID=48141460

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012325758A Abandoned AU2012325758A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine with gamma interferon
AU2012325764A Abandoned AU2012325764A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2012325764A Abandoned AU2012325764A1 (en) 2011-10-20 2012-10-22 Antigen presenting cancer vaccine

Country Status (11)

Country Link
US (2) US20140308316A1 (https=)
EP (2) EP2768519A4 (https=)
JP (2) JP2014530627A (https=)
KR (2) KR20150016200A (https=)
CN (5) CN105999249A (https=)
AU (2) AU2012325758A1 (https=)
CA (2) CA2852960A1 (https=)
HK (2) HK1201175A1 (https=)
IL (2) IL232172A0 (https=)
SG (4) SG11201401631VA (https=)
WO (2) WO2013059784A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2865830B1 (fr) 2004-01-30 2006-05-19 Neopost Ind Systeme d'affranchissement de courrier a mode d'impression externe securise
AU2012325758A1 (en) * 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
CN107109365A (zh) * 2014-07-17 2017-08-29 布莱恩·J·赫尔尼奇 多剂量注射用树突状细胞疫苗的制备及用于阻断her2和her3的联合治疗
CN109416925A (zh) * 2016-05-05 2019-03-01 南托米克斯有限责任公司 检查点失效和使检查点失效的方法
AU2018222737B2 (en) * 2017-02-17 2021-03-25 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells
WO2024107624A1 (en) * 2022-11-14 2024-05-23 Shattuck Labs, Inc. Methods of overcoming resistance to checkpoint inhibitor therapies
CN118441033B (zh) * 2024-04-24 2025-06-20 广西医科大学 HLA-DPB1*05:01在抗γ干扰素自身抗体所致获得性免疫缺陷筛查中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105618C (en) * 1992-09-07 2009-11-03 Kazuyasu Nakamura Humanized antibodies to ganglioside gm2
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
EP1056834A2 (en) 1998-02-20 2000-12-06 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
DK1224264T3 (da) 1999-10-15 2010-05-10 Baylor Res Inst Anvendelse af allogene cellelinjer til at belaste antigenpræsenterende celler til at fremkomme med immunresponser
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
RU2313365C2 (ru) * 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
GB0130720D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Proteins
CN1443778A (zh) * 2002-03-13 2003-09-24 上海中信国健药业有限公司 一种黑色素瘤相关抗原的单克隆抗体及其用途和药物组合物
JP5623004B2 (ja) 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
KR101374091B1 (ko) 2005-07-29 2014-03-17 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
US8076308B2 (en) * 2005-11-07 2011-12-13 British Columbia Cancer Agency Inhibition of autophagy genes in cancer chemotherapy
MY160857A (en) * 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
US20080031900A1 (en) * 2006-06-30 2008-02-07 Baylor Research Institute Dendritic Cells Generated Using GM-CSF and Interferon Alpha and Loaded with Heat-Treated and Killed Cancer Cells
AR060424A1 (es) 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
GB0713116D0 (en) * 2007-07-06 2007-08-15 Therapeutics Ltd E Treatment of melanoma
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same
AU2012325758A1 (en) 2011-10-20 2014-04-24 Neostem Oncology, Llc Antigen presenting cancer vaccine with gamma interferon

Also Published As

Publication number Publication date
CN105999249A (zh) 2016-10-12
EP2768519A2 (en) 2014-08-27
JP2014533938A (ja) 2014-12-18
EP2768519A4 (en) 2015-07-01
HK1201176A1 (en) 2015-08-28
CA2852967A1 (en) 2013-04-25
IL232172A0 (en) 2014-06-30
CA2852960A1 (en) 2013-04-25
NZ623917A (en) 2016-09-30
CN105861437A (zh) 2016-08-17
KR20150004791A (ko) 2015-01-13
IL232173A0 (en) 2014-06-30
AU2012325764A1 (en) 2014-04-24
NZ623915A (en) 2016-02-26
KR20150016200A (ko) 2015-02-11
US20140314814A1 (en) 2014-10-23
HK1201175A1 (en) 2015-08-28
WO2013059778A2 (en) 2013-04-25
CN103957925A (zh) 2014-07-30
US9555058B2 (en) 2017-01-31
WO2013059784A1 (en) 2013-04-25
SG10201508535RA (en) 2015-11-27
JP2014530627A (ja) 2014-11-20
EP2768534A1 (en) 2014-08-27
SG11201401631VA (en) 2014-05-29
SG10201602424RA (en) 2016-05-30
US20140308316A1 (en) 2014-10-16
WO2013059778A3 (en) 2013-07-04
CN105288602A (zh) 2016-02-03
SG11201401632WA (en) 2014-05-29
CN103917246A (zh) 2014-07-09
EP2768534A4 (en) 2015-04-01

Similar Documents

Publication Publication Date Title
Banchereau et al. The differential production of cytokines by human Langerhans cells and dermal CD14+ DCs controls CTL priming
US9555058B2 (en) Antigen presenting cancer vaccine
Escobar et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients
Kim et al. Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Carreno et al. IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunity
Palucka et al. Recent developments in cancer vaccines
US8097242B2 (en) Target CA125 peptides for cancer immunotherapy
Linette et al. Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity
US20170173079A1 (en) Method of Ex Vivo Enhancement of Immune Cell Activity for Cancer Immunotherapy with a Small Molecule Ablative Compound
EP2809775B1 (en) Pluripotent germ layer origin antigen presenting cancer vaccine
US20150191695A1 (en) Composition including gelsolin as effective ingredient for inducing differentiation into dendritic cell and method of inducing differentiation into dendritic cell
Bohnenkamp et al. Breast carcinoma cell lysate-pulsed dendritic cells cross-prime MUC1-specific CD8+ T cells identified by peptide-MHC-class-I tetramers
Hüttner et al. Generation of potent anti-tumor immunity in mice by interleukin-12-secreting dendritic cells
US20170274069A1 (en) Method for the cancer treatment and prevention of metastatic disease
Knudsen et al. Enhanced T‐cell activation by immature dendritic cells loaded with HSP70‐expressing heat‐killed melanoma cells
NZ623917B2 (en) Antigen presenting cancer vaccine
HK1230080A1 (en) Antigen presenting cancer vaccine with gamma interferon
Sconocchia et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for
Biollaz et al. Site-specific anti-tumor immunity: differences in DC function, TGF-β production and numbers of intratumoral Foxp3+ regulatory T cells

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: NEOSTEM ONCOLOGY, LLC

Free format text: FORMER NAME(S): CALIFORNIA STEM CELL, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted